Metastatic Tumor clinical trials at UCSF
1 research study open to eligible people
A metastatic tumor is cancer that has spread to other parts of the body. UCSF is running a study to see how safe a new treatment is for people with advanced tumors. The study aims to find the right dose for the treatment.
NKT3447 for Adults With Advanced/Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).
San Francisco, California and other locations
Last updated: